<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03387956</url>
  </required_header>
  <id_info>
    <org_study_id>IRB00009916</org_study_id>
    <nct_id>NCT03387956</nct_id>
  </id_info>
  <brief_title>Intrathecal Atropine to Prevent Postoperative Nausea and Vomiting</brief_title>
  <official_title>Intravenous Dexamethasone Combined With Intrathecal Atropine to Prevent Morphine-related Nausea and Vomiting After Cesarean Delivery: A Randomized Double-blinded Study</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Assiut University</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Assiut University</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      optimal postoperative pain control with intrathecal morphine, with proper prevention of
      postoperative nausea and vomiting. Dexamethasone, and or atropine could offer some protection
      against nausea and vomiting.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      One of the gold standards for analgesia following cesarean delivery is intrathecal morphine,
      which is not devoid of complications namely postoperative nausea and vomiting. We evaluated
      the antiemetic effect of intravenous dexamethasone combined with intrathecal atropine after
      cesarean delivery under spinal bupivacaine plus morphine anesthesia.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">March 20, 2017</start_date>
  <completion_date type="Actual">August 10, 2017</completion_date>
  <primary_completion_date type="Actual">July 28, 2017</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Prevention</primary_purpose>
    <masking>Double (Participant, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>postoperative nausea</measure>
    <time_frame>24 hours</time_frame>
    <description>Monitoring scale of nausea and vomiting</description>
  </primary_outcome>
  <number_of_arms>3</number_of_arms>
  <enrollment type="Actual">120</enrollment>
  <condition>Postoperative Nausea</condition>
  <arm_group>
    <arm_group_label>Atropine group</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Atropine group (A): Patients received intrathecal heavy Marcaine, 2 ml, 0.5% plus 300 µg morphine and 100 µg atropine (0.5ml), and intravenous injection of 2ml normal saline.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Dexamethasone group</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Dexamethasone group (D): Patients received intrathecal heavy Marcaine 2 ml, 0.5% plus 300 µg morphine (0.5ml), and intravenous 8 mg dexamethasone (2ml).</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Dexamethasone and Atropine group</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Dexamethasone and Atropine group (DA): Patients received intrathecally as group A, plus intravenous injection of 2 ml, dexamethasone 8 mg. Postoperative follow-up of both nausea and vomiting was done over 24 hours postoperative.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Intrathecal atropine</intervention_name>
    <description>100ug intrathecal atropine will be injected with spinal anesthesia</description>
    <arm_group_label>Atropine group</arm_group_label>
    <arm_group_label>Dexamethasone and Atropine group</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>dexamethasone</intervention_name>
    <description>intravenous 8 mg dexamethasone (2ml).</description>
    <arm_group_label>Dexamethasone and Atropine group</arm_group_label>
    <arm_group_label>Dexamethasone group</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  females

          -  18-40 years of age

          -  elective cesarean delivery under bupivacaine spinal anesthesia

        Exclusion Criteria:

          -  renal disease

          -  preeclampsia

          -  liver disease

          -  cardiac disease

          -  Coagulopathy

          -  chronic cough

          -  nausea

          -  vomiting

          -  patient refusal
      </textblock>
    </criteria>
    <gender>Female</gender>
    <gender_based>Yes</gender_based>
    <minimum_age>20 Years</minimum_age>
    <maximum_age>40 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <location>
    <facility>
      <name>Emad Zarief Kamel Said</name>
      <address>
        <city>Assiut</city>
        <zip>71111</zip>
        <country>Egypt</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Egypt</country>
  </location_countries>
  <verification_date>June 2018</verification_date>
  <study_first_submitted>December 20, 2017</study_first_submitted>
  <study_first_submitted_qc>December 24, 2017</study_first_submitted_qc>
  <study_first_posted type="Actual">January 2, 2018</study_first_posted>
  <last_update_submitted>June 4, 2018</last_update_submitted>
  <last_update_submitted_qc>June 4, 2018</last_update_submitted_qc>
  <last_update_posted type="Actual">June 6, 2018</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Assiut University</investigator_affiliation>
    <investigator_full_name>Emad Zarief , MD</investigator_full_name>
    <investigator_title>Dr</investigator_title>
  </responsible_party>
  <keyword>Postoperative Nuasea</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Nausea</mesh_term>
    <mesh_term>Vomiting</mesh_term>
    <mesh_term>Postoperative Nausea and Vomiting</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Dexamethasone</mesh_term>
    <mesh_term>Atropine</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>Undecided</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

